Survival outcomes and dosimetric analysis of Iomab-B (131I-apamistamab) followed by allogeneic hematopoietic cell transplant for patients with TP53 mutated relapsed/refractory AML Meeting Abstract
| Authors: | Natwa, M.; Leung, E.; Chen, M. K.; Wagner, R.; Yap, W.; Griffeth, L.; Wiseman, G.; Wahl, R.; Avril, N.; Lamonica, D.; Vesselle, H.; Passalaqua, S.; Chasen, B.; Johnson, C.; Osborne, J.; Peterson, J.; Menda, Y.; Franceschi, D.; Spross, J.; Li, K.; Desai, A.; Brodin, P.; Pandit-Taskar, N. |
| Abstract Title: | Survival outcomes and dosimetric analysis of Iomab-B (131I-apamistamab) followed by allogeneic hematopoietic cell transplant for patients with TP53 mutated relapsed/refractory AML |
| Meeting Title: | 2024 SNMMI Annual Meeting |
| Journal Title: | Journal of Nuclear Medicine |
| Volume: | 65 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Jun 8-11 |
| Meeting Location: | Toronto, Canada |
| ISSN: | 0161-5505 |
| Publisher: | Society of Nuclear Medicine |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001289165601115 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 241491 -- Source: Wos |
MSK Authors
-
342Pandit-Taskar